IMRNW - （Immuron Limited）

Australia-based Immuron (IMRN) appointed Steven Lydeamore as CEO, effective June 27.The company said Lydeamore recently served as CEO of Anatara Lifesciences.Immuron (IMRN) added…

Key Highlights: North American Travelan sales up by 185% YoY in Q3 FY22 Global sales up 216% YoY in Q3 FY22. YTD March 31, FY22 worldwide Travelan sales reached AU $392K, increasing 340% YoY. MELBOURNE, Australia, April 27, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics

Key Highlights: Immuron''s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award'' Travelan Investigational New Drug (IND) application advances Clinical trial Synopsis complete and plans in place to conduct a controlled human infection model (CHIM) clinical trial in 60 healthy volunteers in the USA MELBOURNE, Australia, April 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ: IMRN ), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to advise that a new request for funding has been considered to be eligible for award by the US Department of Defense funding body ‘Medical Technology Enterprise Consortium'' (MTEC). Immuron is pursuing a regulatory pathway to license Travelan ® with the Food and Drug Administration (FDA) via a Biologics License Application (BLA). The proposed indication is to reduce the risk of contracting travelers'' diarrhea caused by bacterial pathogens.

Immuron <> ADRs have approached the highest level in more than three months after announcing a cash refund of approximately AUD 306K from the Australian government.The refund was…

Immuron (IMRN) has been granted a European Patent for compositions and methods for treating travelers diarrhea

Australia-based Immuron (IMRN) appointed Steven Lydeamore as CEO, effective June 27.The company said Lydeamore recently served as CEO of Anatara Lifesciences.Immuron (IMRN) added…

Key Highlights: North American Travelan sales up by 185% YoY in Q3 FY22 Global sales up 216% YoY in Q3 FY22. YTD March 31, FY22 worldwide Travelan sales reached AU $392K, increasing 340% YoY. MELBOURNE, Australia, April 27, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics

Key Highlights: Immuron''s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award'' Travelan Investigational New Drug (IND) application advances Clinical trial Synopsis complete and plans in place to conduct a controlled human infection model (CHIM) clinical trial in 60 healthy volunteers in the USA MELBOURNE, Australia, April 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ: IMRN ), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to advise that a new request for funding has been considered to be eligible for award by the US Department of Defense funding body ‘Medical Technology Enterprise Consortium'' (MTEC). Immuron is pursuing a regulatory pathway to license Travelan ® with the Food and Drug Administration (FDA) via a Biologics License Application (BLA). The proposed indication is to reduce the risk of contracting travelers'' diarrhea caused by bacterial pathogens.

Immuron <> ADRs have approached the highest level in more than three months after announcing a cash refund of approximately AUD 306K from the Australian government.The refund was…

Immuron (IMRN) has been granted a European Patent for compositions and methods for treating travelers diarrhea

Australia-based Immuron (IMRN) appointed Steven Lydeamore as CEO, effective June 27.The company said Lydeamore recently served as CEO of Anatara Lifesciences.Immuron (IMRN) added…

Key Highlights: North American Travelan sales up by 185% YoY in Q3 FY22 Global sales up 216% YoY in Q3 FY22. YTD March 31, FY22 worldwide Travelan sales reached AU $392K, increasing 340% YoY. MELBOURNE, Australia, April 27, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics

Key Highlights: Immuron''s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award'' Travelan Investigational New Drug (IND) application advances Clinical trial Synopsis complete and plans in place to conduct a controlled human infection model (CHIM) clinical trial in 60 healthy volunteers in the USA MELBOURNE, Australia, April 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ: IMRN ), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to advise that a new request for funding has been considered to be eligible for award by the US Department of Defense funding body ‘Medical Technology Enterprise Consortium'' (MTEC). Immuron is pursuing a regulatory pathway to license Travelan ® with the Food and Drug Administration (FDA) via a Biologics License Application (BLA). The proposed indication is to reduce the risk of contracting travelers'' diarrhea caused by bacterial pathogens.

Immuron <> ADRs have approached the highest level in more than three months after announcing a cash refund of approximately AUD 306K from the Australian government.The refund was…

Immuron (IMRN) has been granted a European Patent for compositions and methods for treating travelers diarrhea